What is an FDA Advisory Committee (AdCom) meeting?

An FDA Advisory Committee meeting is a public meeting where independent medical experts evaluate a drug application and vote on whether its benefits outweigh its risks. Their recommendations are non-binding but the FDA follows them approximately 75-80% of the time.

Are AdCom votes binding on the FDA?

No, AdCom votes are non-binding. The FDA has approved drugs after negative committee votes and has rejected drugs after positive votes. However, the FDA agrees with the committee recommendation about 75-80% of the time.

When does the FDA call an AdCom meeting?

The FDA typically calls an AdCom for first-in-class drugs with novel mechanisms, drugs with safety concerns, marginal or complex efficacy data, controversial endpoints, and treatments with major public health significance. Not all drug applications require an AdCom.

How can I watch an AdCom meeting live?

FDA Advisory Committee meetings are live-streamed on the FDA YouTube channel and the FDA website. Briefing documents from both the sponsor and FDA are published 2-3 days before the meeting.

What happens after a negative AdCom vote?

After a negative AdCom vote, the FDA can still approve the drug with conditions, require additional studies, limit the approved indication, or issue a Complete Response Letter. Approximately 25% of drugs are still approved after receiving a negative advisory committee vote.

Back to Learn

FDA Advisory Committee Meetings

Regulatory

Advisory Committee meetings (AdComs) are public meetings where independent experts evaluate drug applications and provide recommendations to the FDA. They are among the most watched events in biotech.

What is an Advisory Committee?

FDA Advisory Committees are panels of outside experts who provide independent advice on scientific, technical, and policy matters. While their recommendations are non-binding, the FDA follows their guidance approximately 75-80% of the time.

Key Advisory Committees for Drugs

Committee	Abbreviation	Focus Area
Oncologic Drugs Advisory Committee	ODAC	Cancer treatments
Cardiovascular and Renal Drugs	CRDAC	Heart and kidney drugs
Endocrinologic and Metabolic Drugs	EMDAC	Diabetes, obesity
Peripheral and Central Nervous System	PCNS	Neurological drugs
Antimicrobial Drugs	AMDAC	Antibiotics, antivirals
Pulmonary-Allergy Drugs	PADAC	Respiratory conditions

When Does FDA Call an AdCom?

Not all drug applications require an AdCom. The FDA typically calls one when:

Common Triggers

Novel mechanisms - First-in-class drugs
Safety concerns - Unusual adverse events
Efficacy questions - Marginal or complex data
Controversial endpoints - Surrogate vs. clinical outcomes
Accelerated approval - For confirmatory studies
Public health significance - High-profile treatments

Pro Tip: If FDA calls an AdCom, it often signals uncertainty. However, drugs can still be approved even after a negative vote.

AdCom Meeting Structure

Advisory Committee meetings follow a structured format:

Typical Agenda

Morning Session (8:00 AM - 12:00 PM)

FDA presentation of issues
Sponsor presentation of data
FDA review of data

Afternoon Session (1:00 PM - 5:00 PM)

Public comment period
Committee discussion
Voting on questions

Key Documents Released Before Meeting

Document	Timing	Content
Briefing Document (Sponsor)	2-3 days before	Company's case for approval
Briefing Document (FDA)	2-3 days before	FDA's analysis and concerns
Questions for Committee	2-3 days before	Specific questions to be voted on

The Voting Process

Types of Votes

Yes/No Questions

"Do the benefits outweigh the risks?"
"Should this drug be approved?"

Scoring Questions

Scale of 1-5 on specific aspects
Less common but used for nuanced issues

Interpreting Votes

Vote Outcome	Typical Market Reaction
Strong Yes (>70%)	Positive, stock rises
Narrow Yes (50-70%)	Mixed, volatility
Narrow No (40-50%)	Negative but hope remains
Strong No (below 40%)	Significantly negative

Important: AdCom votes are non-binding. The FDA has approved drugs after negative votes and rejected drugs after positive votes.

FDA Response to AdCom

After a Positive Vote

FDA usually follows recommendation (~80% of time)
Final decision still at PDUFA date
May add labeling requirements

After a Negative Vote

FDA can still approve with conditions
May require additional studies
May limit approved indication
Complete Response Letter more likely

Trading Around AdCom Meetings

Pre-AdCom

Briefing documents released 2-3 days before
Stock moves based on FDA's tone in documents
Options premium spikes dramatically

AdCom Day

Meeting is live-streamed (FDA YouTube)
Real-time commentary and vote tallying
Major moves during/after voting

Post-AdCom

Volatility typically decreases
Wait for PDUFA date for final decision
Analyze specific concerns raised

Strategy: Reading FDA briefing documents carefully can provide insights into the agency's concerns before the meeting.

Historical AdCom Statistics

Based on historical data:

Metric	Approximate Rate
FDA follows positive vote	~85%
FDA follows negative vote	~70%
Approval after negative vote	~25%
Rejection after positive vote	~5%

How to Watch AdCom Meetings

Live Streaming

FDA YouTube channel
FDA website

Key Moments to Watch

FDA presentation opening - Sets the tone
Committee Q&A - Reveals concerns
Public comment - Patient perspectives
Final discussion - Committee reasoning
Vote - The main event

Summary

Advisory Committee meetings are critical catalysts that provide insight into FDA thinking:

Non-binding but highly influential recommendations
Called for complex, novel, or controversial drugs
Briefing documents released 2-3 days before
Live-streamed for public transparency
75-80% FDA agreement with committee votes

← Previous: PDUFA Dates

Next: NDA vs BLA →